AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27748014 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 81
Study 27748014 — intervention group
Group type: COMPARATOR
Intervention: DBs
Number of subjects: 81
Study 26031760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower UPSIT scores (impaired odor identification)
Number of subjects: 1169
Study 26031760 — intervention group
Group type: EXPERIMENTAL
Intervention: First quartile of UPSIT scores
Number of subjects: 1169
Study 26031760 — intervention group
Group type: EXPERIMENTAL
Intervention: Second quartile of UPSIT scores
Number of subjects: 1169
Study 26031760 — intervention group
Group type: EXPERIMENTAL
Intervention: Third quartile of UPSIT scores
Number of subjects: 1169
Study 26031760 — intervention group
Group type: COMPARATOR
Intervention: Fourth quartile of UPSIT scores (highest scores)
Number of subjects: 1169
Study 23747131 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy: omeprazole 20mg, amoxicillin 1g, clarithromycin 500 mg, and tinidazole 500 mg for 5 days
Number of subjects: 270
Study 23747131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy: omeprazole 20mg and amoxicillin 1g for 5 days followed by omeprazole 20mg, clarithromycin 500 mg, and tinidazole 500 mg for 5 days
Number of subjects: 270
Study 23747131 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid therapy: omeprazole 20mg, and amoxicillin 1g for 7 days followed by omeprazole 20mg, amoxicillin 1g, clarithromycin 500 mg, and tinidazole 500 mg for 7 days
Number of subjects: 270
Study 23747131 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy: omeprazole 20mg, levofloxacin 250 mg, and amoxicillin 1g, all given twice daily for 10 days
Number of subjects: 270
Study 20665553 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study 20665553 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label treatment
Number of subjects: 0
Study 20665553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19722254 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-Diaminopyridine (DAP) up to 75-80 mg/day
Number of subjects: 7
Study 19722254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 17189464 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 106
Study 17189464 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 106
Study 17189464 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery with post-operative rehabilitation
Number of subjects: 106
Study 17189464 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty with post-operative rehabilitation
Number of subjects: 106
Study 16039961 — intervention group
Group type: COMPARATOR
Intervention: Closed tracheal suction system (CTSS)
Number of subjects: 15
Study 16039961 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially ventilated endotracheal suction method (PVETS)
Number of subjects: 15
Study 12131981 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (mentholated deionized water)
Number of subjects: 200
Study 12131981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate + 0.05% sodium fluoride
Number of subjects: 200
Study 12131981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate
Number of subjects: 200
Study 12131981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% stevioside + 0.05% sodium fluoride (pH 3.4)
Number of subjects: 200
Study 10613374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet splitting using a tablet splitter
Number of subjects: 0
Study 10613374 — intervention group
Group type: COMPARATOR
Intervention: Tablet splitting
Number of subjects: 0
Study 8970693 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 days of methadone detoxification
Number of subjects: 1803
Study 8970693 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 days of methadone detoxification
Number of subjects: 1803
Study 1747217 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of elemental calcium in the form of oystershell electrolysate (AA calcium)
Number of subjects: 0
Study 6186187 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg/dose)
Number of subjects: 47
Study 6186187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 6186187 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 47
Study 30448094 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed crystalloid at 37°C
Number of subjects: 60
Study 30448094 — intervention group
Group type: COMPARATOR
Intervention: Room temperature crystalloid
Number of subjects: 60
Study 29674605 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain training games (BTG) using Lumosity for 15 min per day, at least 7 days per week, for 3 weeks
Number of subjects: 51
Study 29674605 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain training games (BTG) using Lumosity
Number of subjects: 51
Study 29674605 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=21)
Number of subjects: 51
Study 26231286 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-obturator tape (TOT)
Number of subjects: 87
Study 26231286 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 87
Study 24679444 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI 2 mg (IAI 2Q4)
Number of subjects: 188
Study 24679444 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 188
Study 23017384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ottawa Influenza Decision Aid (OIDA)
Number of subjects: 107
Study 23017384 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study 20060571 — intervention group
Group type: EXPERIMENTAL
Intervention: Road traffic noise exposure (n=280, L(eq,24h)=67±2dB(A))
Number of subjects: 659
Study 20060571 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=379, L(eq,24h)=58.7±6dB(A))
Number of subjects: 659
Study 17546842 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed flour (30 g/day, 5 g of alpha-linolenic acid)
Number of subjects: 24
Study 17546842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (manioc flour)
Number of subjects: 24
Study 16383055 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based composite inlays (Paradigm, 3M ESPE)
Number of subjects: 80
Study 16383055 — intervention group
Group type: COMPARATOR
Intervention: Porcelain inlays (Vita Mark II, Vita Zahnfabrik)
Number of subjects: 80
Study 16383055 — intervention group
Group type: COMPARATOR
Intervention: Both materials (Resin-based composite and Porcelain)
Number of subjects: 80
Study 12058009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment initiated in early adolescence
Number of subjects: 224
Study 12058009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment initiated in later adolescence
Number of subjects: 224
Study 9707299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid mixture
Number of subjects: 15
Study 9707299 — intervention group
Group type: COMPARATOR
Intervention: Placebo mixture
Number of subjects: 15
Study 8577212 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.a.d.
Number of subjects: 20
Study 8577212 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d.
Number of subjects: 20
Study 8577212 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 45 mg b.i.d.
Number of subjects: 20
Study 8577212 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg b.i.d.
Number of subjects: 20
Study 8577212 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.i.d.
Number of subjects: 20
Study 2225893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabsorbable paste containing 2% tobramycin, 2% amphotericin B, and 2% polymyxin E applied locally to decontaminate the oropharynx.
Number of subjects: 28
Study 2225893 — intervention group
Group type: COMPARATOR
Intervention: Paste without antibiotics applied to the oropharynx (Control group).
Number of subjects: 28
Study 371057 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine, 1 mg/ml
Number of subjects: 10
Study 371057 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study 371057 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 10
Study 28551060 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Dexmedetomidine (100μg) in Group BD
Number of subjects: 93
Study 28551060 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine in Group B
Number of subjects: 93
Study 28551060 — intervention group
Group type: COMPARATOR
Intervention: Saline in Group C
Number of subjects: 93
Study 27852903 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/day)
Number of subjects: 171
Study 27852903 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (35 mg/week)
Number of subjects: 171
Study 24444658 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) twice-daily (DUAL A1)
Number of subjects: 101
Study 24444658 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) once-daily (DUAL A2)
Number of subjects: 101
Study 24444658 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) twice-daily + PegIFN/RBV (QUAD B1)
Number of subjects: 101
Study 24444658 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) once-daily + PegIFN/RBV (QUAD B2)
Number of subjects: 101
Study 24444658 — intervention group
Group type: EXPERIMENTAL
Intervention: Asunaprevir (200 mg) twice-daily + ribavirin (TRIPLE B3)
Number of subjects: 101
Study 22362907 — intervention group
Group type: COMPARATOR
Intervention: Frequent hemodialysis (1.5‐2.75 hours, six times per week)
Number of subjects: 0
Study 22362907 — intervention group
Group type: COMPARATOR
Intervention: Frequent hemodialysis (6‐8 hours, six times per week)
Number of subjects: 0
Study 22362907 — intervention group
Group type: COMPARATOR
Intervention: Frequent hemodialysis (six sessions per week)
Number of subjects: 0
Study 22362907 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal hemodialysis
Number of subjects: 0
Study 22362907 — intervention group
Group type: COMPARATOR
Intervention: Frequent hemodialysis
Number of subjects: 0
Study 20063238 — intervention group
Group type: EXPERIMENTAL
Intervention: Zestra (topical botanical preparation)
Number of subjects: 256
Study 20063238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 18280328 — intervention group
Group type: EXPERIMENTAL
Intervention: Six doses of activated charcoal (50 g each at 4-hour intervals)
Number of subjects: 4632
Study 18280328 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of activated charcoal (50 g)
Number of subjects: 4632
Study 18280328 — intervention group
Group type: COMPARATOR
Intervention: No activated charcoal
Number of subjects: 4632
Study 15992199 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention in nursing homes
Number of subjects: 1169
Study 15992199 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 1169
Study 12687557 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg body weight) at weeks 0, 2, and 6
Number of subjects: 20
Study 12687557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10562681 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified type III radical neck dissection (MRND)
Number of subjects: 132
Study 10562681 — intervention group
Group type: COMPARATOR
Intervention: Lateral neck dissection (LND)
Number of subjects: 132
Study 8545692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus fluid therapy
Number of subjects: 9
Study 8545692 — intervention group
Group type: COMPARATOR
Intervention: No fluid
Number of subjects: 9
Study 8545692 — intervention group
Group type: COMPARATOR
Intervention: Maintenance fluid
Number of subjects: 9
Study 1878583 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX: 12 g/m2 as 4-hour infusion)
Number of subjects: 130
Study 1878583 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose methotrexate (IDMTX: 1 g/m2 as 36-hour infusion)
Number of subjects: 130
Study 1878583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation from HLA-compatible siblings
Number of subjects: 130
Study 1878583 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with daily oral thioguanine and biweekly intravenous (IV) MTX
Number of subjects: 130
Study 1878583 — intervention group
Group type: EXPERIMENTAL
Intervention: Reprophylaxis to the CNS with IV/intrathecal (IT) MTX
Number of subjects: 130
Study 1878583 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor analyses
Number of subjects: 130
Study 6617676 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (mean 127 mg/day, range 37-225)
Number of subjects: 22
Study 6617676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29889597 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-targeted treatment (BT) phase (left/right judgments and touch discrimination training)
Number of subjects: 10
Study 29889597 — intervention group
Group type: COMPARATOR
Intervention: Usual care (education, strengthening, and stretching training)
Number of subjects: 10
Study 29889597 — intervention group
Group type: COMPARATOR
Intervention: No-treatment phase
Number of subjects: 10
Study 30503111 — intervention group
Group type: EXPERIMENTAL
Intervention: D&C plus ACP gel
Number of subjects: 149
Study 30503111 — intervention group
Group type: COMPARATOR
Intervention: D&C alone
Number of subjects: 149
Study 27500951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28
Study 27500951 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 28
Study 24791578 — intervention group
Group type: EXPERIMENTAL
Intervention: Total energy intake (100-kcal increment)
Number of subjects: 8428
Study 24791578 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting 5% of energy from fat by protein
Number of subjects: 8428
Study 24791578 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting 5% of energy from carbohydrate by protein
Number of subjects: 8428
Study 22290044 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injections
Number of subjects: 22
Study 22290044 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injections
Number of subjects: 22
Study 20080363 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based substance abuse prevention program (12-hour curriculum)
Number of subjects: 7079
Study 20080363 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 7079
Study 18725699 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying a load of 10% or 20% of body weight with feet spaced shoulder width apart or together for 45 seconds
Number of subjects: 0
Study 18725699 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying a briefcase, single strapped bag, or purse
Number of subjects: 0
Study 18725699 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing with feet together (decreased base of support)
Number of subjects: 0
Study 15965311 — intervention group
Group type: EXPERIMENTAL
Intervention: LY450139 (50 mg/day for 14 days)
Number of subjects: 37
Study 15965311 — intervention group
Group type: COMPARATOR
Intervention: LY450139 (5 mg, 20 mg, 40 mg doses)
Number of subjects: 37
Study 15965311 — intervention group
Group type: EXPERIMENTAL
Intervention: LY450139 (50 mg/day)
Number of subjects: 37
Study 15965311 — intervention group
Group type: EXPERIMENTAL
Intervention: LY450139 (all doses)
Number of subjects: 37
Study 12810924 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA + MTX
Number of subjects: 61
Study 12810924 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 61
Study 11086589 — intervention group
Group type: EXPERIMENTAL
Intervention: Arizona Pilot Project treatment (capitation)
Number of subjects: 0
Study 11086589 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (fee-for-service)
Number of subjects: 0
Study 11086589 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment administration sites
Number of subjects: 0
Study 11086589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment functional level
Number of subjects: 0
Study 11086589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercepts as predictors in structural models
Number of subjects: 0
Study 9071904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR) 200 mg/day
Number of subjects: 24
Study 9071904 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 24
Study 7690396 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF) 5 micrograms/Kg/day
Number of subjects: 86
Study 7690396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 3521047 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 300 (non-ionic contrast medium)
Number of subjects: 22
Study 3521047 — intervention group
Group type: EXPERIMENTAL
Intervention: Rayvist 300 (ionic contrast medium)
Number of subjects: 22
Study 3521047 — intervention group
Group type: COMPARATOR
Intervention: Both contrast media with optimal hydration
Number of subjects: 22
Study 31880804 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) added to standard front-line chemotherapy
Number of subjects: 0
Study 31880804 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) for patients with activating signaling mutations
Number of subjects: 0
Study 29465434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of circulation-derived CD34+ cells (1.0 × 10 cells/each vessel; n = 18)
Number of subjects: 38
Study 29465434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of circulation-derived CD34+ cells (3.0 × 10 cells/each vessel; n = 20)
Number of subjects: 38
Study 29465434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of circulation-derived CD34+ cells
Number of subjects: 38
Study 28012706 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (30mg single dose)
Number of subjects: 0
Study 28012706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26658988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nereu Program (n = 54)
Number of subjects: 113
Study 26658988 — intervention group
Group type: COMPARATOR
Intervention: Usual counselling (n = 59)
Number of subjects: 113
Study 23220098 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex
Number of subjects: 84
Study 23220098 — intervention group
Group type: EXPERIMENTAL
Intervention: CinnoVex
Number of subjects: 84
Study 23220098 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 84
Study 21823414 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 11
Study 21823414 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Carbamazepine)
Number of subjects: 11
Study 18292808 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0
Study 17262141 — intervention group
Group type: EXPERIMENTAL
Intervention: Etching with 10% hydrofluoric acid for 2 min (G1)
Number of subjects: 60
Study 17262141 — intervention group
Group type: EXPERIMENTAL
Intervention: Etching with 10% hydrofluoric acid for 4 min (G2)
Number of subjects: 60
Study 17262141 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-microm particle aluminum oxide sandblasting for 5 s (G3)
Number of subjects: 60
Study 17262141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting followed by etching for 2 min (G4)
Number of subjects: 60
Study 17262141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting followed by etching for 4 min (G5)
Number of subjects: 60
Study 17262141 — intervention group
Group type: COMPARATOR
Intervention: Control - no treatment (G6)
Number of subjects: 60
Study 14586718 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (26 patients)
Number of subjects: 49
Study 14586718 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors (23 patients)
Number of subjects: 49
Study 10618303 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced short-term scaling exponent alpha(1) <0.75
Number of subjects: 446
Study 10618303 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced alpha(1)
Number of subjects: 446
Study 9127846 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension-assisting brace
Number of subjects: 40
Study 9127846 — intervention group
Group type: COMPARATOR
Intervention: Accelerated rehabilitation programme without brace
Number of subjects: 40
Study 8459060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (8.0 +/- 2.0 mg/liter)
Number of subjects: 12
Study 8459060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30282349 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercises in addition to traditional treatment (infrared radiation and continuous ultrasound)
Number of subjects: 34
Study 30282349 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (infrared radiation and continuous ultrasound)
Number of subjects: 34
Study 30282349 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercises in addition to traditional treatment
Number of subjects: 34
Study 29185931 — intervention group
Group type: EXPERIMENTAL
Intervention: J‐aggregated zeaxanthin dipalmitate formulation (10 mg free zeaxanthin)
Number of subjects: 16
Study 29185931 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐aggregated zeaxanthin dipalmitate formulation (10 mg free zeaxanthin)
Number of subjects: 16
Study 26109247 — intervention group
Group type: EXPERIMENTAL
Intervention: PEERS program (treatment group, n = 12)
Number of subjects: 22
Study 26109247 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control (control group, n = 10)
Number of subjects: 22
Study 24415445 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 780
Study 24415445 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 780